← Back to NOVELIX PHARMACEUTICALS LIMITE Overview
📊Financials📈PE Ratio🥧Shareholding💰Dividend📋Quarterly⚖️Balance Sheet💹P&L🌊Cash Flow
NOVELIXHealthcare Research, Analytics & Technology

NOVELIX PHARMACEUTICALS LIMITE — Financial Ratios & Key Metrics

₹55.78
-3.48%
P/E Ratio104.85xIndustry: 45.95x
ROE0.64%Return on equity
ROCE0.96%Return on capital
Debt/Equity0.00Debt free ✓
💎

Valuation & Profitability

P/E Ratio
104.85x
Industry Average P/E
45.95x
Dividend Yield
0.00%
Market Cap
₹101.70 (Cr)
Sales Growth 5Y
82.92%
Profit Growth 5Y
-2.33%
EPS Growth 5Y
-6.26%
OPM 5Y Avg
-12.77%
📉

Price Returns

1 Month
+18.77%
3 Months
+48.75%
6 Months
+125.52%
1 Year
+173.96%
52W Low
₹27
Current
₹56
52W High
₹70
67% of 52-week range — Mid range
🔬

Technical Indicators

49RSI 14
Neutral
Momentum is balanced — neither overbought nor oversold.
SMA 50
₹58
▼ Price below SMA 50 — Bearish
SMA 200
₹49
▲ Long-term uptrend
Volume Signal
58% of avg
Below average volume — low conviction

Technical indicators are for educational purposes only. Not investment advice.

More on NOVELIX PHARMACEUTICALS LIMITE

OverviewFinancialsPE HistoryShareholdingQuarterlyBalance SheetP&LCash FlowHealthcare Research, Analytics & Technology StocksScreener

Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.